Pharmaceutical composition comprising a human GLP-1 mimetibody

Details Pharmaceutical composition comprising a human GLP-1 mimetibody Pharmaceutical composition comprising a human GLP-1 mimetibody

2007-07-18

2011-12-06

Chandra, Gyan (Department: 1646)

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

C530S308000, C530S387100, C514S001100

Reexamination Certificate

active

08071103

ABSTRACT:
The present invention relates to at least one improved human GLP-1 mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 mimetibody or specified portion or variant, GLP-1 mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5118666 (1992-06-01), Habener
patent: 5428130 (1995-06-01), Capon et al.
patent: 5512549 (1996-04-01), Chen et al.
patent: 5545618 (1996-08-01), Buckley et al.
patent: 5908626 (1999-06-01), Chang et al.
patent: 5977071 (1999-11-01), Galloway et al.
patent: 6406697 (2002-06-01), Capon et al.
patent: 2004/0053370 (2004-03-01), Glaesner et al.
patent: 2004/0096935 (2004-05-01), Shi et al.
patent: 1 355 942 (2003-10-01), None
patent: 1 408 050 (2004-04-01), None
patent: 1 559 724 (2005-08-01), None
patent: WO 98/08871 (1998-03-01), None
patent: WO 00/69911 (2000-11-01), None
patent: WO 01/98331 (2001-12-01), None
patent: WO 2004/002424 (2004-01-01), None
patent: WO 2005/005604 (2004-06-01), None
patent: WO 2005/097175 (2005-10-01), None
Adelhorst, et al., “Structure-Activity Studies of Glucagon-like Peptide-1,” The Journal of Biological Chemistry, 269(9): 6275-6278 (1994).
Chou, et al., “Conformational Parameters for Amino Acids in Helical, β-Sheet, and Random Coil Regions Calculated from Proteins,” Biochemistry, 13(2): 211-222 (1974).
Marquesee, et al., “Helix stabilization by Glu—. . . Lys+salt bridges in short peptides ofde novodesign,” Proceedings of the National Academy of Sciences USA, 84: 8898-8902 (1987).
Maxfield, et al., “The Effect of Neighboring Charges on the Helix Forming Ability of Charged Amino Acids in Proteins,” Macromolecules, 8(4): 491-493 (1975).
Thornton, et al., “Structure of Glucagon-like peptide (7-36) Amide in a Dodecylphosphocholine Micelle as Determined by 2D NMR,” Biochemistry, 33: 3532-3539 (1994).
Sarmay, et al, “Mapping and Comparison of the Interaction Sites on The Fc Region of IgG Responsible for Triggering Antibody Dependent Cellular Cytotoxicity (ADCC) Through Different Types of Human Fcγ Receptor,” Molecular Immunology, 29(5): 633-639 (1992).
Bird, et al., “Single-Chain Antigen-Binding Proteins,” Science, 242: 423-426 (1988).
Parker, et al., “Structure-function analysis of a series of glucagon-like peptide-1 analogs,” Journal of Peptide Research, 52: 398-409 (1998).
Kim, et al., “FT-IR and Near-Infared FT-Raman Studies of the Secondary Structure of Insulinotropin in the solid State: α-Helix to β-Sheet Conversion Induced by Phenol and/or by High Shear Force,” Journal of Pharmaceutical Sciences, 83(8): 1175-1180 (1994).
PCT International Search Report dated Jul. 4, 2008.

Affiliated with

Also associated with

Rating

Pharmaceutical composition comprising a human GLP-1 mimetibody does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical composition comprising a human GLP-1 mimetibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition comprising a human GLP-1 mimetibody will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4313220